Humanity faces serious challenges in 2022: climate change threatens the planet; global health crises have exposed vulnerabilities in society; communities are being marginalised; and demographic trends are creating new pressures on healthcare worldwide. To meet these challenges, pioneering family-owned Boehringer Ingelheim is working on breakthrough therapies with the hope of transforming lives.
First established in Germany in 1885 and now one of the top 20 pharmaceutical companies in the world, Boehringer Ingelheim specialises in areas of unmet medical need in three business areas – Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Bruno Rizzuti joined Boehringer Ingelheim in 2014 and took up his role as Head of Data Management in 2020. "Big Pharma companies listen to their employees, this is something you can immediately tell when you join a pharma company,” says Rizzuti. “This is important because happy people give better results."
Innovation is another attractive, industry-wide aspect of the profession, he says. "You cannot survive in pharma if you don't innovate. You must innovate in new treatments and in new therapeutic areas. This is an industry that has innovation at its essence. And that also makes it a wonderful place to grow; you always have new challenges."